Scientists have developed an anti-HIV antiviral strategy for scientists working in human liver primates, which provide guidelines for identifying targets and doses for human immunization potential.
According to a new study published in the Immunity journal, Rhesus macaque monkeys can produce neutralizing antibodies against HIV strain, the Tier 2 virus is a form of virus-resistant infected people.
"The neutralizing antibody induced by vaccines protects against anti-virus animals, because they are like real-world liver disease," said Dennis Burton, head of the Department of Immunology and Microbiology of Scripps Researche.
Even though the vaccine is far from the clinical trial, Burton and his colleagues developed the concept of HIV virus strategy from the 1990's.
Research also has provided the necessary preventive rates to neutralize anti-vaccine antibodies against HIV.
The effective vaccination strategy must be used by the external protein of the virus to trimer the immune system before creating the appropriate antibodies. But the compact proteins remain unstable and remain in isolation, according to the study.
The researchers designed a more stable trimer or SOSIP genetics and designed an experimental HIV virus called SOSIP trimer stable.
The group tested the vaccine in both Rhesus makaqueen groups.
Previous studies by vaccine demonstrated that some immunized monkeys developed low levels of antibody low neutralizer or antibody levels in the body, while others developed high-grade vaccines.
From this study, the researchers detected and reloaded six monkeys and six great monkeys. Likewise, 12 unimmunized primates were used as control groups.
After that, the primates had a form of virus called Shiv, in the simian version of the HIV virus.
This unique tension of the virus is known as the Tier 2 virus, because it has shown its desire to neutralize it, like many forms that circulate in the human population.
The researchers found the vaccine in high-grade animals. Monkeys can have sufficient levels of neutralizing antibodies against trimer protein envelopes to prevent infection.
Following antibody levels while viruses are exposed to animals continuously, the researchers have to confirm the necessary qualifications to keep HIV.
Forward, scientists seek to improve the design of vaccines for human testing and maintain high titles.